Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06680830 | A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | PHASE2 | RECRUITING | 150 | — | — | Jan 17, 2025 | Sep 1, 2027 | Apr 24, 2026 | 70 | United States, Israel +4 |
| Arm | Type | Description |
|---|---|---|
| NEU-411 | EXPERIMENTAL | Orally-administered NEU-411 |
| Placebo | PLACEBO_COMPARATOR | Orally-administered matching placebo |
| Name | Type | Description |
|---|---|---|
| NEU-411 | DRUG | NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity |
| Placebo | OTHER | Orally-administered matched placebo |
Inclusion Criteria: 1. Aged 40-80 years at time of screening, inclusive 2. Diagnosis of clinically established or clinically probable Parkinson's Disease (PD) 3. LRRK2-driven PD using the investigational companion diagnostic genetic test (CDx) 4. Modified Hoehn and Yahr (mH\&Y) of 1 to 2.5 Exclusi...